Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGlobalHealth specialty pharmacy Prior Auth Coverag…
    Ask Trek AI about this page
    CurrentglobalhealthPolicy N/A

    Prior authorization and coverage criteria for specialty pharmacy products (partial)

    Customize your policy alerts

    Sign up for all globalhealth policy alerts

    Know when globalhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document provides prior authorization requirements and coverage criteria for specific specialty pharmacy products for GlobalHealth Medicare Advantage plans; it affects prescribers and pharmacies submitting PA requests for the listed drugs.

    Policy Summary
    Payerglobalhealth
    PolicyPrior authorization and coverage criteria for specialty pharmacy products (partial)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewJul 21, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with required clinical documentation (e.g., disease severity measures, prior therapy trials, specialist consult notes) to support approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+products shown (partial)
    12 monthscommon PA duration
    24TYMLOS duration limit
    All FDA-approvedindication scope repeated

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria (Per-Product Summaries)

    TYMLOS — Initial therapy

    Covered when ALL of the following are met:

    TYMLOS initial coverage: Patient meets an FDA‑approved indication for abaloparatide (TYMLOS) for osteoporosis; total cumulative duration of abaloparatide therapy will not exceed 24 months.24 MONTHS

    ORENCIA — Initial and renewal

    Covered when ALL of the following are met:

    ORENCIA initial: Indication-specific prescriber: RA and PJIA prescribed by or in consultation with a rheumatologist; PsA prescribed by or in consultation with a dermatologist or rheumatologist. RA initial requires trial of or contraindication to 3 months of one conventional synthetic DMARD (if methotrexate tried, dose ≥20 mg/week or maximally tolerated). No concurrent use with another systemic biologic or targeted small molecule for the same indication.3 months DMARD trial; methotrexate >=20 mg/week if tried
    ORENCIA renewal: Renewal requires documentation the member continues to benefit from therapy and that there is no concurrent use with another systemic biologic or targeted small molecule for the same indication.continued benefit

    Oncology agents — Initial

    Covered when the product‑specific PA criteria are met for FDA‑approved oncology indications:

    Oncology agents (examples): Product is prescribed for an FDA‑approved oncology indication listed for the agent (e.g., VERZENIO, abiraterone products); required documentation and prescriber restrictions per the product entry are provided. Typical authorization duration is 12 months.12 MONTHS

    ATTR-CM: Initial/Renewal

    Initial authorization for ATTR‑CM is covered when ALL of the following are met:

    ATTR-CM initial criteria: 1) Patient has NYHA class I, II, or III heart failure; AND 2) Diagnosis of transthyretin‑mediated amyloidosis confirmed by (A) strongly positive Tc‑99m‑PYP bone scan demonstrating myocardial uptake, OR (B) tissue biopsy with chemical typing confirming transthyretin (TTR) protein. Prescribed by or in consultation with a cardiologist, ATTR specialist, or medical geneticist; no concurrent use with other ATTR‑CM TTR stabilizers (e.g., tafamidis).

    Adalimumab products: Initial

    Initial authorization for adalimumab products is covered when ALL of the following are met (requirements vary by indication):

    Psoriasis initial: Plaque psoriasis covering ≥3% body surface area OR psoriatic lesions affecting hands, feet, face, scalp, or genital area; plus required trials of topical/systemic therapies or phototherapy per product entry unless contraindicated or switching from another biologic.>=3% BSA
    Rheumatoid arthritis initial: Trial of or contraindication to 3 months of one conventional synthetic DMARD (e.g., methotrexate); if methotrexate was tried, trial at ≥20 mg/week or maximally tolerated dose is required. Prescriber restrictions (e.g., rheumatologist) apply per indication.>=20 mg/week when methotrexate trialed

    Initial and Renewal Criteria (examples)

    Covered when ALL of the following are met (examples extracted from product entries):

    RA initial example: Trial of or contraindication to 3 months of one conventional synthetic DMARD; if methotrexate tried, dose ≥20 mg/week or maximally tolerated dose required.
    Psoriasis initial example: Plaque psoriasis covering ≥3% BSA or lesions affecting hands/feet/face/scalp/genitalia AND at least a 3‑month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA unless contraindicated/intolerant.3% BSA
    Ankylosing spondylitis initial example: Trial of or contraindication to an NSAID prior to biologic therapy.
    Renewal example: For renewal (commonly 12 months), documentation that the member continues to benefit from the medication is required.

    Per-product PA coverage summaries (partial)

    Covered when the product‑specific PA criteria, prescriber restrictions, and documentation requirements are met:

    ARIKAYCE initial/renewal: Initial and renewal requests must be prescribed by or in consultation with a pulmonologist or infectious disease specialist. Renewal requires microbiological response and symptomatic improvement (first renewal: ≥1 negative MAC sputum culture by 6 months; second/subsequent renewals: ≥3 negative MAC sputum cultures by 12 months).
    Kineret (anakinra): Indications such as CAPS and DIRA require confirmatory genetic testing or inflammatory marker evidence plus clinical features; for RA initial therapy requires trial or contraindication to two preferred agents and no concurrent systemic biologic/targeted small molecule for the same indication.
    Other listed agents (summary): Many specialty products require PA for FDA‑approved indications, with typical authorization durations of 12 months and potential prescriber restrictions; see individual product entry for detailed clinical criteria.12 MONTHS

    Otezla initiation and renewal

    Otezla initiation pack covered when ALL of the following are met:

    Mild plaque psoriasis initial: Patient meets any of: psoriasis covering <3% BSA OR SPGA score of 2 OR PASI score 2–9; and trial of or contraindication to one conventional systemic therapy (e.g., methotrexate, acitretin, cyclosporine) OR one conventional topical therapy (e.g., topical corticosteroids).
    Moderate-to-severe plaque psoriasis initial: Psoriasis covering ≥3% BSA OR lesions affecting hands/feet/face/scalp/genital area; AND at least a 3‑month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA, or documented contraindication/intolerance.BSA >= 3%
    General Otezla rules: No concurrent use with another systemic biologic or targeted small molecule for the same indication; renewal requires demonstrated continued benefit (renewal typically 12 months).

    Asciminib (Scemblix) initial therapy

    Covered when ALL of the following are met:

    Scemblix (asciminib) initial: Indication: previously treated Ph+ CML or T315I mutation per product labeling; mutational analysis (BCR‑ABL1 profile) performed prior to initiation and therapy aligns with NCCN guideline recommendations based on mutation profile.

    Miplyffa (NPC) initial and renewal

    Covered when ALL of the following are met:

    Miplyffa (NPC) initial: Prescribed by or in consultation with a neurologist or geneticist; initial authorization 6 months and renewal 12 months; renewal requires evidence of improvement or slowing of disease progression per product entry.

    Qulipta coverage

    Covered when ALL of the following are met:

    Qulipta initial: Indication: migraine prevention as labeled; initial authorization 6 months, renewal 12 months; no concurrent use with other CGRP inhibitors for migraine.

    Avacopan (Tavneos) coverage

    Covered when ALL of the following are met:

    Avacopan (Tavneos) initial: Indication: ANCA‑associated vasculitis (ANCA seropositive anti‑PR3 or anti‑MPO); prescribed by or in consultation with a rheumatologist or nephrologist; initial/renewal duration 6 months and renewal requires continued benefit documentation.

    Ayvakit and AVMAPKI co-pack

    Covered when the PA criteria for each product are met:

    Ayvakit initial: Coverage per FDA‑approved indications; authorization duration commonly 12 months as listed in product entry.
    AVMAPKI co‑pack initial: Coverage per FDA‑approved indications; authorization duration commonly 12 months as listed in product entry.

    Per-product criteria (partial)

    Per the product entries in this segment, coverage is allowed when the listed PA elements are satisfied:

    General product PA attributes: PA record includes required clinical information, prescriber specialty (if specified), required prior therapy trials (if specified), and supports FDA‑approved indication; many entries list a typical authorization duration of 12 months.
    REZUROCK - chronic GVHD: For chronic graft‑versus‑host disease: failure of at least two lines of systemic therapy is required, one of which must be a trial of or contraindication to JAKAFI.
    BENLYSTA - SLE: Prescribed by or in consultation with a rheumatologist; initial authorization 6 months and renewal 12 months; initial SLE requires concurrent use of standard background therapies and renewal requires documented clinical improvement.

    Per-product PA summaries (partial)

    These product summaries list PA parameters; approval requires meeting the entry‑specific clinical and administrative requirements:

    Sample listed products: Products in this window (e.g., REZUROCK, WELIREG, MEKTOVI, BORTEZOMIB) require PA for FDA‑approved indications with durations commonly 12 months; see individual product line for specific clinical criteria.

    Bosentan: Initial Therapy

    Covered when ALL of the following are met:

    Bosentan initial PA criteria: Diagnosis of pulmonary arterial hypertension confirmed by right heart catheterization with mean PAP >20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; prescribed by or in consultation with a cardiologist or pulmonologist; baseline liver tests acceptable and no concurrent use of cyclosporine A or glyburide; avoid use if ALT/AST >3×ULN or bilirubin increase ≥2×ULN.see node text

    Bosutinib: Initial Therapy

    Covered when ALL of the following are met:

    Bosutinib initial PA criteria: Diagnosis of previously treated Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML); mutational analysis (BCR‑ABL1 profile) performed prior to initiation and Bosulif appropriate per NCCN guideline table; prerequisite therapy required per product entry.

    HAEGARDA: Initial Therapy

    Covered when ALL of the following are met:

    HAEGARDA initial PA criteria: Diagnosis of hereditary angioedema (Type III or Type I/II confirmed by complement testing: C1‑INH protein, C4, C1‑INH functional levels, C1q); prescribed by or in consultation with a hematologist, immunologist, allergist or pulmonologist; not on concurrent alternative prophylactic HAE agent.

    General product PA stance

    General PA coverage rules apply:

    General product PA stance: Products listed in this formulary segment are subject to prior authorization; coverage generally limited to FDA‑approved indications and many entries indicate a default authorization period of 12 months unless otherwise specified.

    EPIDIOLEX

    Covered when ALL of the following are met:

    EPIDIOLEX initial: Indication: Dravet syndrome, Lennox‑Gastaut syndrome, or tuberous sclerosis complex; prescribed by or in consultation with a neurologist; for LGS an initial trial of or contraindication to two therapies is required (example: clonazepam); initial/renewal durations and other prerequisites per product entry.
    EPIDIOLEX renewal: Renewal: routinely 12 months; documentation of continued benefit required.

    Carglumic acid

    Covered when ALL of the following are met:

    Carglumic acid indications: Covered for acute or chronic hyperammonemia due to NAGS deficiency (confirmed by biochemical or genetic testing), acute hyperammonemia due to propionic acidemia (confirmed by elevated methylcitric acid or genetic testing), or acute hyperammonemia due to methylmalonic acidemia (confirmed by elevated methylmalonic/methylcitric acid or genetic testing).
    Carglumic acid duration rules: Acute hyperammonemia due to NAGS/PA/MMA: up to 7 days; chronic HA due to NAGS: initial authorization 6 months with renewal 12 months contingent on documented clinical improvement.7 DAYS; 6 MOS initial; 12 MOS renewal

    CIMZIA-STARTER: Initial and Renewal Coverage Criteria

    Covered when ALL of the following are met for specified indications:

    CIMZIA‑STARTER plaque psoriasis: Plaque psoriasis covering ≥3% BSA OR lesions affecting hands/feet/face/scalp/genital area.BSA >= 3%
    CIMZIA‑STARTER NR‑axSpA: Non‑radiographic axial spondyloarthritis: objective support with elevated CRP above ULN OR sacroiliitis on MRI.
    Prescriber restriction: For certain diagnoses (RA, AS, NR‑axSpA, PJIA) prescription must be by or in consultation with a specialist (e.g., rheumatologist).
    Step therapy: Initial approval requires trial of or contraindication to specified preferred agents (number and agents vary by indication); step requirement waived if patient is pregnant, breastfeeding, or trying to become pregnant.

    Product-level general coverage statements

    Covered when consistent with product labeling and required documentation:

    FDA indication alignment: Request supports an FDA‑approved indication for the product and required clinical documentation (labs, imaging, prior therapy trials, prescriber specialty) is provided as specified in the product entry.
    Default duration: Where the product entry specifies a default authorization period, the usual duration is 12 months unless otherwise noted.12 months

    General PA coverage for listed products

    Coverage summarized per product entries in this segment; approval requires meeting the per‑product PA elements:

    General PA coverage rules: Most listed specialty products require prior authorization for FDA‑approved indications; when specified, authorization durations are commonly 12 months and Part B applicability is noted per entry.

    Dasatinib specific coverage criterion

    Covered when ALL of the following are met:

    Dasatinib prerequisites: For previously treated Philadelphia chromosome‑positive CML: mutational analysis (BCR‑ABL1 profile) performed prior to initiation and dasatinib use is appropriate per NCCN guideline recommendations based on mutation profile.

    Dalfampridine ER specific coverage criterion

    Covered when ALL of the following are met:

    Dalfampridine ER initial: Prescribed by or in consultation with a neurologist and documentation of walking disability symptoms (e.g., mild to moderate bilateral lower extremity impairment) is provided.

    TAFINLAR soluble tablet criterion

    Covered when ALL of the following are met:

    TAFINLAR soluble tablet authorization: Soluble tablet formulation authorized when patient is unable to swallow TAFINLAR capsules; PA criteria apply and authorization duration typically 12 months.

    Deferasirox — Initial and Renewal Coverage Criteria

    Covered when ALL of the following are met for the specified indications:

    Transfusion‑dependent chronic iron overload (initial): Serum ferritin consistently >1000 mcg/L; prescribed by or in consultation with a hematologist or hematologist/oncologist; initial authorization 6 months.serum ferritin >1000 mcg/L
    NTDT initial: Serum ferritin consistently >300 mcg/L (at least two lab values in prior 3 months) AND liver iron concentration (LIC) ≥5 mg Fe/g dry weight; prescribed by or in consultation with a hematologist; initial authorization 6 months.ferritin >300 mcg/L; LIC >=5 mg Fe/g
    Renewal criteria: Transfusion‑dependent renewal: serum ferritin consistently >500 mcg/L. NTDT renewal: ferritin >300 mcg/L (two labs) OR LIC ≥3 mg Fe/g dry weight; renewal authorization 12 months.

    Diclofenac topical — OA knee

    Covered when ALL of the following are met:

    Topical diclofenac for OA knee: Documented diagnosis of osteoarthritis of the knee and trial of alternative agents where required per product entry; authorization durations vary (example entry lists 6 months).

    General product coverage

    Covered when the claim meets product‑specific criteria listed in the formulary:

    General product coverage: Request supports an FDA‑approved indication and required clinical documentation (prescriber specialty, labs, prior trials) is provided as specified; many entries state a default authorization period of 12 months.

    Droxidopa Initial/Renewal

    Covered when ALL of the following are met:

    Droxidopa initial criteria: Baseline blood pressure readings while sitting and within 3 minutes of standing are documented; orthostatic drop of ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes after standing demonstrated; prescribed by or in consultation with a neurologist or cardiologist.>=20 mmHg systolic or >=10 mmHg diastolic within 3 minutes of standing
    Droxidopa renewal: Renewal authorization: 12 months if patient continues to benefit from therapy.

    DUPIXENT Initial/Renewal/Exclusions

    DUPIXENT is covered when ALL indication‑specific diagnostic and prior therapy requirements are met:

    Eosinophilic asthma initial: Blood eosinophil count 150–1500 cells/mcL within the past 12 months; concurrent therapy with an appropriate dose of inhaled corticosteroid and one other maintenance medication; evidence of poor control (e.g., corticosteroid burst ≥3 days within past 12 months or serious exacerbation) as specified in product entry.eosinophils 150-1500 cells/mcL
    CRSwNP initial: 56‑day trial of one topical nasal corticosteroid AND evidence of nasal polyps by exam/endoscopy/CT AND inadequately controlled disease per product entry.
    General exclusion: No concurrent use with another systemic biologic or targeted small molecule for the same indication.

    Dronabinol Coverage

    Covered when ALL of the following are met:

    Dronabinol initial (nausea/vomiting): Indication: nausea and vomiting associated with cancer; prior authorization required; authorization duration commonly 6 months per product entry.

    ADA‑SCID coverage (REVCOVI)

    Covered when ALL of the following are met:

    REVCOVI initial for ADA‑SCID: Confirmatory genetic test OR suggestive laboratory findings (e.g., elevated deoxyadenosine nucleotide levels, lymphopenia) plus hallmark clinical signs/symptoms (recurrent infections, failure to thrive, persistent diarrhea); prescribed by or in consultation with an immunologist, hematologist/oncologist, or physician specializing in inherited metabolic disorders. Initial authorization 6 months; renewal 12 months contingent on improvement or maintenance of immune function.

    CFTR modulator coverage (TRIKAFTA)

    Covered when ALL of the following are met:

    TRIKAFTA initial: Prescribed by or in consultation with a pulmonologist or cystic fibrosis expert; not used concurrently with another CFTR modulator; initial authorization 6 months (renewal per product entry, often lifetime thereafter).

    Multiple myeloma coverage (ELREXFIO)

    Covered when ALL of the following are met:

    ELREXFIO initial: Initial approval for relapsed/refractory multiple myeloma as listed in the product entry; initial authorization 6 months. Renewal requires documentation of clinical response; for relapsed/refractory disease renewal requires at least 24 weeks of prior treatment and response for at least 2 months.

    Eltrombopag coverage (ITP and other indications)

    Covered when ALL of the following are met for ITP and other indications:

    Eltrombopag initial for ITP: Platelet count <30 x10^9/L OR platelet count <50 x10^9/L with a prior bleeding event; trial of or contraindication to one corticosteroid or IVIG or insufficient response to splenectomy; prescribed by or in consultation with a hematologist or immunologist; no concurrent use with other thrombopoietin receptor agonists. Initial authorization 6 months.
    Eltrombopag formulation preference: For oral suspension packets, trial of a formulary tablet version is required OR documentation that the patient cannot tolerate the tablet formulation.
    Eltrombopag renewal: Renewal: improvement in platelet counts from baseline or reduction in bleeding events AND no concurrent use with other TPO‑RAs; renewal authorization 12 months.

    ORSERDU coverage

    Covered when ALL specified PA elements are met:

    ORSERDU coverage: PA required for FDA‑approved indications; authorization duration commonly 12 months per product entry.

    Initial therapy (ITP)

    Covered when ALL of the following are met:

    ITP initial coverage: 1) Platelet count <30 x10^9/L OR platelet count <50 x10^9/L with a prior bleeding event; 2) Trial of or contraindication to splenectomy; 3) Prescribed by or in consultation with a hematologist or immunologist; 4) No concurrent use with other TPO‑RAs; 5) For oral suspension packets, trial of a formulary tablet version or documented inability to tolerate/swallow tablets.

    Continuation / renewal (ITP)

    Covered when ALL of the following are met for continuation:

    ITP renewal: 1) Demonstrated improvement in platelet counts from baseline or reduction in bleeding events; 2) No concurrent use with other thrombopoietin receptor agonists; 3) Prescriber remains a hematologist or immunologist. Renewal authorization: 12 months.

    Abaloparatide (TYMLOS) is subject to prior authorization and is covered only for FDA‑approved osteoporosis indications with a maximum cumulative treatment duration of 24 months. Requests that would result in total therapy beyond 24 months are excluded and may be denied.

    Several product entries explicitly prohibit concurrent use of multiple agents for the same indication. Examples include: ATTR‑CM agents (e.g., ATTRUBY) — no concurrent use with other ATTR‑CM TTR stabilizers (e.g., tafamidis); and multiple biologic/targeted therapies for inflammatory indications (e.g., adalimumab family and related starters) — no concurrent use with another systemic biologic or targeted small molecule (for the same indication). These concurrent‑use exclusions are enforced at initial authorization and renewal.

    For uveitis indications the policy excludes isolated anterior uveitis in the listed adalimumab/related product entries: if the request is for isolated anterior uveitis it does not meet the documented initial criteria and is not eligible for coverage under that indication.

    Initial Therapy — Criteria by Drug

    inv-246: TYMLOS initial

    TYMLOS initial: Coverage allowed for FDA‑approved osteoporosis indications provided cumulative use does not exceed 24 months.24 MONTHS

    inv-247: ATTR-CM initial

    ATTR‑CM initial: NYHA class I–III AND diagnostic confirmation by strongly positive Tc‑99m‑PYP bone scan OR tissue biopsy with transthyretin typing; prescribed by or in consultation with appropriate specialist; no concurrent use with other ATTR‑CM TTR stabilizers.

    inv-248: Adalimumab initial

    Adalimumab initial (summary):

    Renewal / Continuation Criteria

    inv-264: Abatacept continuation

    Abatacept continuation: Renewal for abatacept (ORENCIA) requires documentation that the member continues to benefit from therapy and no concurrent use with another systemic biologic or targeted small molecule for the same indication.

    inv-265: Renewal criteria

    Renewal criteria (general): Renewal requests require evidence the patient continues to benefit from therapy; renewal intervals commonly 12 months where specified.

    inv-266: Renewal/Continuation

    Renewal/continuation: Demonstration of continued clinical benefit is required for renewal across many products; documentation of symptom improvement or laboratory/imaging response as specified in the product entry is expected.

    Prior Authorization and Documentation — Actions for Prescribers/Pharmacies

    Prior Authorization

    TYMLOS prior authorization

    Prior authorization required for TYMLOS (abaloparatide). Total cumulative coverage is limited to 24 months; requests exceeding a cumulative 24-month treatment duration will not be approved.

    • Coverage duration limit: 24 MONTHS
    Prior Authorization

    ORENCIA prior authorization

    Prior authorization required for ORENCIA (IV and SC). Initial requests for RA/PJIA must be prescribed by or in consultation with a rheumatologist (PsA by or in consultation with a dermatologist or rheumatologist); RA initial requires trial of or contraindication to 3 months of one conventional synthetic DMARD (if methotrexate tried, ≥20 mg/week or maximally tolerated dose). Renewal requires documentation of continued benefit and no concurrent use with another systemic biologic or targeted small molecule.

    • Prescriber restriction: rheumatologist for RA/PJIA; dermatologist or rheumatologist for PsA
    • RA prerequisite: 3-month trial of one conventional synthetic DMARD (methotrexate ≥20 mg/week if tried)

    Coding and Billing Identifiers

    Products Listedmixed
    CALQUENCE ORAL TABLETacalabrutinib product listing
    Products Listedmixed
    ATTRUBYacoramidis product listing
    Products Listedmixed
    HUMIRAadalimumab branded product and starter kits
    adalimumab-aatyadalimumab-aaty biosimilar presentations (various pen/syringe configurations)
    YUFLYMAadalimumab biosimilar product presentations
    Adalimumab product identifiers listedmixed
    adalimumab-aaty1 pen auto-injector kit 40 mg/0.4ml or 80 mg/0.8ml
    adalimumab-adbm
    adalimumab-bwwd
    Products Affected (Cyltezo and starters)mixed
    CYLTEZO (2 PEN)
    CYLTEZO (2 SYRINGE)
    CYLTEZO-CD/UC/HS STARTER
    CYLTEZO-PSORIASIS/UV STARTER
    Hadlima productsmixed
    HADLIMA
    HADLIMA PUSHTOUCH
    Piqray dosing products affectedmixed
    PIQRAY (200 MG DAILY DOSE)
    PIQRAY (300 MG DAILY DOSE)
    Formulary Identifiersmixed
    Formulary ID: 26380Formulary identifier shown for Otezla/ Otezla XR initiation pack
    Covered product identifiers (trade names) shownmixed
    MEKTOVIProduct name listed under 'Products Affected'
    Covered product identifiersmixed
    bortezomib injection solution reconstituted 1 mg, 2.5 mg, 3.5 mgBortezomib formulations listed
    Covered product identifiersmixed
    bosentan oral tabletbosentan oral tablet
    Covered product identifiersmixed
    BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MGbosutinib oral tablet
    Covered product identifiersmixed
    HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNITC1 esterase inhibitor - HAEGARDA
    Covered product identifiersmixed
    COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MGCometriq product listing
    COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MGCometriq product listing
    Products Affected (example)mixed
    COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MGProduct listing text
    Products Affected (example)mixed
    COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MGProduct listing text
    Products Affectedmixed
    TABRECTAProduct name as listed
    Products Affectedmixed
    EPIDIOLEXProduct name as listed
    Products Affectedmixed
    carglumic acid oral tablet solubleProduct name as listed
    Formulary identifiersmixed
    Formulary ID: 26380Identifier for CIMZIA-STARTER entry
    Drugs listed in segment (no billing codes provided)mixed
    No codes listed
    Products listed by namemixed
    INQOVIProduct name listed (decitabine/cedazuridine)
    OSENVELTdenosumab-bmwo
    VUMERITYdiroximel fumarate
    Deferasirox formulationsmixedCovered
    deferasirox granulesdeferasirox formulation
    deferasirox oral tabletdeferasirox formulation
    Topical diclofenac productsmixedCovered
    diclofenac sodium external solution 2%topical diclofenac product
    diclofenac epolamine externaltopical diclofenac patch/agent
    Neurology / MS related productsmixedCovered
    AUSTEDOdeutetrabenazine formulations
    dimethyl fumarate oral capsule delayed releasedimethyl fumarate formulations
    Products listed (examples)mixed
    ORSERDU ORAL TABLET 345 MG, 86 MGProduct strengths listed in formulary entry
    CFTR modulator productmixed
    TRIKAFTA ORAL TABLET THERAPY PACKElexacaftor‑tezacaftor‑ivacaftor therapy pack
    Multiple myeloma productmixed
    ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9MLElranatamab‑bcmm formulations
    Eltrombopag formulationsmixed
    eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mgPROMACTA tablet strengths
    eltrombopag olamine oral packet 12.5 mg, 25 mgPROMACTA suspension packets
    ADA‑SCID therapymixed
    REVCOVIElapegademase‑lvlr product name
    Covered drug productsNDCCovered
    eltrombopag olamine oral tablet 12.5 mgListed product affected
    eltrombopag oral suspension packetsListed formulation with trial requirement
    Maximum cumulative duration for abaloparatide (TYMLOS)
    Maximum cumulative duration24 MONTHS (total treatment duration for abaloparatide [TYMLOS] must not exceed 24 months)

    Step Therapy Requirements

    RequirementDetails
    Required prior DMARD trial before initiating abatacept for RA
    Trial of or contraindication to 3 months of one conventional synthetic DMARD (e.g., methotrexate). If methotrexate was tried, it must have been at ≥20 mg/week or the maximally tolerated dose.
    RequirementDetails
    Requires prior trials of conventional therapies or documented contraindication
    For plaque psoriasis and related indications: at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or phototherapy (PUVA), or contraindication/intolerance; topical/systemic therapies or phototherapy required per indication.
    RequirementDetails
    Trial of specified agents prior to biologic therapy
    Examples include a trial of oral immunosuppressants or PUVA for psoriasis and trial of an NSAID for ankylosing spondylitis; documentation of trial and inadequate response or contraindication required.
    RequirementDetails
    step
    For rheumatoid arthritis (Kineret) a trial of or contraindication to two preferred agents is required prior to initiation.
    RequirementDetails
    Trial of specified prior therapies required before Otezla initiation
    Mild plaque psoriasis: trial of or contraindication to one conventional systemic therapy (e.g., methotrexate, acitretin, cyclosporine) or one conventional topical therapy. Moderate-to-severe: at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA, or contraindication/intolerance.
    RequirementDetails
    Required before coverage for CGVHD indications
    For chronic graft‑versus‑host disease (cGVHD): failure of at least two lines of systemic therapy is required, one of which must be a trial of or contraindication to JAKAFI.
    RequirementDetails
    Prerequisite therapy references in entries
    Some product entries indicate 'Prerequisite Therapy: Yes' or list required prior agents; specific sequencing may vary by product and indication.
    RequirementDetails
    Prerequisite therapy required for bosutinib
    Bosutinib (Bosulif) lists 'Prerequisite Therapy: Yes' and requires mutational analysis prior to initiation per NCCN recommendations; specific prior therapy details are referenced in the product entry.
    RequirementDetails
    Must document trial or contraindication
    EPIDIOLEX LGS indication: initial trial of or contraindication to two specified therapies (example: clonazepam) must be documented.
    RequirementDetails
    Step agents required for many indications unless exception applies
    CIMZIA‑STARTER and similar entries require trials of specified preferred agents (number varies by indication); step requirements are waived for patients who are pregnant, breastfeeding, or trying to conceive.
    RequirementDetails
    Prescribed by or in consultation with a neurologist required for initial dalfampridine ER
    Dalfampridine ER initial requests must be prescribed by or in consultation with a neurologist and include documentation of walking disability symptoms (e.g., bilateral lower extremity impairment).
    RequirementDetails
    Trial or documentation of contraindication required prior to approval
    Examples: deferasirox requires trial of or contraindication to generic deferasirox oral tablet or suspension; topical diclofenac for OA knee requires trial of alternative agents per product entry.
    RequirementDetails
    Prerequisite therapy required for some DUPIXENT indications
    For atopic dermatitis: trial of topical agents (e.g., corticosteroid, calcineurin inhibitor, PDE‑4 or JAK inhibitor) or documentation of contraindication. For eosinophilic asthma: evidence of concurrent ICS and another maintenance med plus eosinophil thresholds and prior exacerbation/control criteria.
    RequirementDetails
    Trial of formulary tablet required before approving oral suspension packets
    Eltrombopag oral suspension packets require a trial of a formulary tablet version or documentation that the patient cannot tolerate the tablet formulation or has difficulty swallowing.
    RequirementDetails
    Trial of or contraindication to splenectomy required for ITP; formulation trial rules
    Initial ITP: document platelet count thresholds (<30 x10^9/L or <50 x10^9/L with prior bleeding), trial of or contraindication to splenectomy, and no concurrent use of other TPO‑RAs. For suspension packets, trial of tablet formulation or inability to tolerate tablets is required.

    Background and Scope

    This document provides prior authorization requirements and coverage criteria for multiple specialty pharmacy products used by GlobalHealth Medicare Advantage plans. It covers products across therapeutic areas — for example, osteoporosis (abaloparatide/TYMLOS), transthyretin‑mediated amyloidosis (ATTRUBY), and numerous biologic and oncology agents — and specifies required clinical documentation, prescriber restrictions, prerequisite therapy trials, and standard authorization durations (commonly 6 or 12 months). Notable policy limits include a 24‑month cumulative duration cap for abaloparatide (TYMLOS), diagnostic confirmation and specialist prescribing requirements for ATTR‑CM, and restrictions prohibiting concurrent use of multiple systemic biologic or targeted small‑molecule therapies for the same indication.

    Definitions and Diagnostic Thresholds

    Conventional synthetic DMARD definition
    DefinitionConventional synthetic DMARDs are traditional disease‑modifying antirheumatic drugs (example: methotrexate)
    Role in step therapyRequired prerequisite therapy before many biologics (document trial of at least 3 months or contraindication)
    Example agent and dosingMethotrexate — if tried, at least 20 mg/week or maximally tolerated dose
    ATTR-CM diagnostic confirmation
    Confirmatory testsStrongly positive Tc‑99m‑PYP bone scan OR tissue biopsy with chemical typing confirming transthyretin (TTR)
    Clinical requirementNYHA class I, II, or III heart failure documented

    Revision History

    Policy Summary
    Payerglobalhealth
    PolicyPrior authorization and coverage criteria for specialty pharmacy products (partial)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewJul 21, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with required clinical documentation (e.g., disease severity measures, prior therapy trials, specialist consult notes) to support approval.
    SourceLink
    On This Page
    Coverage Criteria (Per-Product Summaries)Initial Therapy — Criteria by DrugRenewal / Continuation CriteriaPrior Authorization and Documentation — Actions for Prescribers/PharmaciesCoding and Billing IdentifiersStep Therapy RequirementsBackground and ScopeDefinitions and Diagnostic ThresholdsRevision History
    12 months renewal interval typical
    No concurrent therapy: No concurrent use with another systemic biologic or targeted small molecule for the same indication.
    Duration: Initial duration may be 6 months for some indications; renewals typically 12 months with documentation of continued benefit.6 months initial (some), 12 months renewal
    Indication‑specific criteria: e.g., plaque psoriasis ≥3% BSA or other listed features; RA requires trial of or contraindication to 3 months of a conventional synthetic DMARD (methotrexate ≥20 mg/week if tried).
    >=3% BSA; methotrexate >=20 mg/week if tried

    inv-249: Initial therapy prerequisites

    Initial therapy prerequisites (examples): Indication‑specific prerequisite therapy is required (e.g., psoriasis: 3‑month trial of an oral immunosuppressant or PUVA; RA: 3‑month DMARD trial at appropriate dose), or documentation of contraindication/intolerance.

    inv-250: ARIKAYCE initial

    ARIKAYCE initial: Prescribed by or in consultation with a pulmonologist or infectious disease specialist; initial authorization 6 months; patient meets MAC lung disease criteria per product entry.

    inv-251: Kineret initial

    Kineret initial: For RA: prescribed by or in consultation with a rheumatologist and trial of or contraindication to two preferred agents required; CAPS/DIRA require genetic or inflammatory marker confirmation and clinical features.

    inv-252: Onapgo initial

    Onapgo initial: Initial prescription by or in consultation with a neurologist for Parkinson disease; initial/renewal duration 12 months; renewal requires documented improvement in motor symptoms.

    inv-253: Otezla initial therapy

    Otezla initiation: Meets criteria for mild or moderate‑to‑severe plaque psoriasis as defined (BSA, SPGA, PASI) and prior therapy trials or contraindications documented; no concurrent systemic biologic/targeted small molecule for same indication.

    inv-254: Scemblix initial therapy

    Scemblix initial: Mutational analysis prior to initiation and alignment with NCCN treatment recommendations for BCR‑ABL1 mutation profile; coverage duration commonly 12 months.

    inv-255: BENLYSTA initial therapy

    BENLYSTA initial: Prescribed by or in consultation with a rheumatologist for SLE; initial authorization 6 months; patient receiving standard background SLE therapies; renewal 12 months with documented clinical improvement.

    inv-256: Prerequisite therapy notes (partial)

    Prerequisite therapy notes: Some product entries indicate prerequisite therapy (Prerequisite Therapy: Yes) or specific prior agent trials; details are product specific and must be documented.

    inv-257: Bosentan initial therapy

    Bosentan initial: PAH diagnosis confirmed by right heart catheterization (mean PAP >20 mmHg, PCWP ≤15 mmHg, PVR >2 Wood units); prescribed by or in consultation with appropriate specialist; baseline LFTs acceptable and no concurrent use with cyclosporine A or glyburide; avoid if ALT/AST >3×ULN or bilirubin ≥2×ULN.

    inv-258: EPIDIOLEX Initial Therapy

    EPIDIOLEX initial: Prescribed by or in consultation with a neurologist for DS, LGS, or TSC; for LGS initial trial of or contraindication to two therapies required (example clonazepam); initial/renewal durations per product entry.

    inv-259: Initial therapy requirements

    CIMZIA‑STARTER initial requirements: Initial: trial of or contraindication to preferred agents as specified by indication; prescriber specialty requirements for certain diagnoses; documentation of disease severity and prior therapy required; initial durations vary (commonly 6 months for some indications).

    inv-260: Deferasirox — Initial Therapy

    Deferasirox initial: Transfusion‑dependent: serum ferritin consistently >1000 mcg/L. NTDT: serum ferritin >300 mcg/L (two values in prior 3 months) AND LIC ≥5 mg Fe/g dry weight. Prescribed by or in consultation with a hematologist; initial authorization 6 months.see node text

    inv-261: DUPIXENT initial

    DUPIXENT initial (AD example): For atopic dermatitis: intractable pruritus or skin breakdown AND trial of or contraindication to one topical agent (topical corticosteroid, calcineurin inhibitor, PDE‑4 inhibitor, or JAK inhibitor) as specified.

    inv-262: Initial therapy requirements

    Select initial coverage durations and prescriber requirements: Examples: REVCOVI initial 6 months with specialist prescribing and diagnostic confirmation; TRIKAFTA initial 6 months with pulmonologist/CF expert and no concurrent CFTR modulator; ELREXFIO initial 6 months; eltrombopag initial 6 months for ITP with platelet thresholds and prior therapy trial documented.

    inv-263: Initial therapy (ITP)

    ITP initial (eltrombopag): Platelet count <30 x10^9/L OR platelet count <50 x10^9/L with prior bleeding; trial of or contraindication to splenectomy; prescribed by or in consultation with a hematologist or immunologist; no concurrent use with other TPO‑RAs; for suspension packets, trial of tablet formulation or inability to tolerate tablets is required. Initial duration: 6 months.

    inv-267: ARIKAYCE continuation

    ARIKAYCE continuation: Renewal requires no positive MAC sputum culture after consecutive negative cultures AND symptom improvement; first renewal: ≥1 negative MAC sputum culture by 6 months; second/subsequent renewals: ≥3 negative MAC sputum cultures by 12 months.

    inv-268: Kineret continuation

    Kineret continuation: Renewal intervals: RA initial 6 months, renewal 12 months; CAPS/DIRA may have lifetime authorization for some indications; renewal requires continued benefit documentation.

    inv-269: Otezla renewal

    Otezla renewal: Renewal requires documentation that the patient continues to benefit from therapy; renewal duration commonly 12 months.

    inv-270: Renewal criteria (partial)

    Renewal notes (partial): Bosentan renewal: continued avoidance of contraindicated concurrent medications (e.g., cyclosporine A, glyburide) and acceptable liver tests; HAEGARDA renewal: not on concurrent alternative prophylactic HAE agent. Renewal durations commonly 12 months.

    inv-271: CIMZIA-STARTER renewal

    CIMZIA‑STARTER renewal: Renewal requires documentation that the patient continues to benefit from the medication for the indicated condition; renewal duration typically 12 months.

    inv-272: Deferasirox — Continuation Therapy

    Deferasirox continuation: Transfusion‑dependent renewal: serum ferritin consistently >500 mcg/L. NTDT renewal: ferritin >300 mcg/L (two labs) OR LIC ≥3 mg Fe/g dry weight. Renewal duration: 12 months.

    inv-273: Droxidopa renewal

    Droxidopa renewal: Renewal: 12 months if patient continues to benefit from therapy, with required documentation of clinical response as specified.

    inv-274: DUPIXENT renewal

    DUPIXENT renewal: Indication‑specific improvement on therapy required for renewal (examples: reduction in exacerbations or rescue med use, increased FEV1, or symptom reduction for asthma; improvement in pruritus/lesions for PN); renewal durations per product entry (commonly 12 months).

    inv-275: Renewal/continuation therapy requirements

    Renewal/continuation summary: Examples: REVCOVI renewal 12 months contingent on improvement or maintenance of immune function; ELREXFIO renewal 12 months with specified response/time‑on‑therapy requirements; eltrombopag renewal 12 months with improvement in platelet counts and no concurrent TPO‑RA use.

    inv-276: Renewal (ITP)

    ITP renewal: Improvement in platelet counts from baseline or reduction in bleeding events AND no concurrent use with other TPO‑RAs; renewal duration typically 12 months.
  1. No concurrent use with another systemic biologic or targeted small molecule
  2. Renewal: document continued benefit
  3. Prior Authorization

    Oncology agents prior authorization

    Prior authorization is required for listed oncology agents (e.g., VERZENIO, abiraterone products). Coverage durations are commonly set to 12 months; approval must align with the product’s PA criteria and indication-specific requirements.

    • Typical coverage duration: 12 MONTHS
    • Indications limited to All FDA‑approved Indications unless otherwise specified
    Prior Authorization

    CALQUENCE (acalabrutinib) – PA required

    Prior authorization required for CALQUENCE (acalabrutinib) oral tablet. PA entries list a 12‑month coverage duration and require adherence to the product-specific PA criteria in the formulary entry.

    • Coverage duration: 12 MONTHS
    • Follow product PA criteria as listed in formulary
    Prior Authorization

    ATTRUBY (acoramidis) – PA required

    Prior authorization required for ATTRUBY (acoramidis) for transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM). Initial requests must document NYHA class I–III and diagnosis confirmed by a strongly positive Tc‑99m‑PYP bone scan or tissue biopsy with transthyretin typing; requests must be prescribed by or in consultation with a cardiologist, ATTR specialist, or medical geneticist. Concurrent use with other ATTR‑CM TTR stabilizers is not allowed.

    • Diagnostic documentation: NYHA class I–III AND positive Tc‑99m‑PYP scan OR biopsy with TTR chemical typing
    • Prescriber: cardiologist, ATTR specialist, or medical geneticist
    • No concurrent use with other ATTR‑CM TTR stabilizers
    • Initial/renewal duration: 12 MONTHS
    Prior Authorization

    Adalimumab products – PA required

    Prior authorization required for adalimumab products. Initial approvals require indication‑specific documentation (e.g., plaque psoriasis ≥3% BSA or lesions on hands/feet/face/scalp/genitalia) and required prior therapy trials such as conventional systemic/topical therapies or immunosuppressants; concurrent use with another systemic biologic or targeted small molecule for the same indication is prohibited.

    • Psoriasis severity: ≥3% BSA or involvement of hands/feet/face/scalp/genitalia
    • RA prerequisite: trial of or contraindication to 3 months of one conventional synthetic DMARD (methotrexate ≥20 mg/week if tried)
    • No concurrent use with another systemic biologic or targeted small molecule
    Step Therapy

    Prior authorization with prerequisite therapy

    Prior authorization often requires evidence of prerequisite therapy; the specific prerequisite varies by indication (for example, RA requires a 3‑month trial of a conventional synthetic DMARD, and psoriasis commonly requires trials of topical/systemic therapies or phototherapy).

    • Document trials of specified prior therapies or contraindications per indication (e.g., methotrexate ≥20 mg/week when used)
    • Step therapy requirements differ by indication — confirm applicable list in product entry
    Prior Authorization

    Prior authorization required

    Prior authorization is required for the listed specialty products; approval durations and other criteria are specified per product entry — many products have a common 12‑month authorization period.

    • Confirm product‑specific PA criteria and stated coverage duration (commonly 12 months)
    Prior Authorization

    ARIKAYCE PA specifics

    ARIKAYCE (amikacin liposomal) PA requires prescribing by or in consultation with a pulmonologist or infectious disease specialist. Renewal requires microbiological and clinical response: first renewal requires at least one negative MAC sputum culture by 6 months; second and subsequent renewals require at least three negative MAC sputum cultures by 12 months, plus symptomatic improvement.

    • Prescriber restriction: pulmonologist or infectious disease specialist
    • Renewal evidence: ≥1 negative MAC sputum culture by 6 months for first renewal; ≥3 negative cultures by 12 months for subsequent renewals
    • Renewal also requires clinical improvement in symptoms
    Documentation Required

    PA requires disease severity and prior therapy documentation

    Prior authorization requests must include disease severity measures and documentation of prior therapies or contraindications when required (examples: psoriasis BSA/SPGA/PASI scores, prior systemic or topical treatment trials for Otezla). Failure to provide these objective severity or prior‑therapy records may lead to denial.

    • Provide BSA, SPGA, or PASI scores for psoriasis where requested
    • Include documented trials of prior therapies or contraindications per indication
    Documentation Required

    PA requires mutational analysis

    Prior authorization for certain targeted agents (e.g., Scemblix/asciminib) requires mutational analysis prior to initiation and alignment with NCCN treatment recommendations based on BCR‑ABL1 mutation profile.

    • Submit mutational analysis (BCR‑ABL1) demonstrating appropriateness of therapy per NCCN guidance
    Prior Authorization

    Prior authorization required (12-month durations noted)

    Prior authorization is required for many listed products and commonly provides a 12‑month approval interval; verify Part B applicability in the product entry (often 'No').

    • Common coverage duration: 12 MONTHS
    • Confirm Part B applicability per entry
    Prior Authorization

    BENLYSTA PA timing

    BENLYSTA (belimumab) PA: initial authorization is for 6 months and renewal for 12 months; initial requests should be prescribed by or in consultation with a rheumatologist and include documentation of concurrent standard SLE therapy and clinical improvement on renewal.

    • Initial duration: 6 months; renewal: 12 months
    • Prescriber: rheumatologist or in consultation with rheumatology
    • Initial: evidence of concomitant SLE therapy (corticosteroids, antimalarials, NSAIDs, or immunosuppressive agents); renewal: clinical improvement required
    Prior Authorization

    Prior authorization required (multiple products)

    Prior authorization is required for many additional products in the formulary; most entries indicate a 12‑month coverage duration and product‑specific PA criteria must be met.

    • Confirm product‑specific PA criteria and documentation requirements
    • Typical authorization period: 12 MONTHS
    Prior Authorization

    MEKTOVI prior authorization

    MEKTOVI (binimetinib) requires prior authorization with a coverage duration listed as 12 months and coverage limited to FDA‑approved indications per the formulary entry.

    • Coverage duration: 12 MONTHS
    • Indications: All FDA‑approved Indications
    Prior Authorization

    Bortezomib prior authorization

    Bortezomib products require prior authorization; the formulary lists a 12‑month coverage duration and coverage is limited to FDA‑approved indications.

    • Coverage duration: 12 MONTHS
    • Indications: All FDA‑approved Indications
    Prior Authorization

    Bosentan prior authorization

    Bosentan prior authorization requires diagnostic confirmation of PAH by right heart catheterization (mean PAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units), prescriber specialty involvement, baseline liver tests, and no concurrent use with cyclosporine A or glyburide. Coverage/renewal durations are listed as 12 months.

    • RHC confirmation with mean PAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units
    • Do not authorize if ALT/AST >3x ULN or bilirubin increase ≥2x ULN
    • No concurrent use with cyclosporine A or glyburide
    • Coverage duration: 12 MONTHS
    Prior Authorization

    Bosutinib prior authorization

    Bosutinib (Bosulif) requires prior authorization with prior mutational analysis (BCR‑ABL1 mutation profile) before initiation and indicates prerequisite therapy; coverage duration is 12 months.

    • Submit BCR‑ABL1 mutational analysis prior to initiation
    • Prerequisite therapy indicated (see product entry)
    • Coverage duration: 12 MONTHS
    Prior Authorization

    HAEGARDA prior authorization

    HAEGARDA prior authorization required for hereditary angioedema (HAE). Initial requests must include complement testing to confirm Type I/II HAE (C1‑INH protein, C4, C1‑INH function, C1q) or documentation consistent with Type III HAE, be prescribed by or in consultation with an appropriate specialist, and note no concurrent prophylactic HAE agent; initial/renewal duration: 12 months.

    • Required labs: C1‑INH protein, C4, C1‑INH functional levels, C1q
    • Prescriber: hematologist, immunologist, allergist, or pulmonologist
    • No concurrent use with alternative prophylactic HAE agent
    • Coverage duration: 12 MONTHS
    Prior Authorization

    Cometriq prior authorization

    Cometriq products are listed as subject to prior authorization in the formulary; consult the product PA entry for specific criteria.

    • Check the product entry for detailed PA criteria
    Prior Authorization

    Prior authorization required

    Prior authorization is required for many listed products; review each product entry for detailed PA criteria and typical 12‑month coverage periods.

    • Confirm product‑specific PA criteria and documentation
    Prior Authorization

    EPIDIOLEX prior auth specifics

    EPIDIOLEX requires prior authorization with specialist prescription (neurologist) for DS, LGS, and TSC; for LGS an initial trial of or contraindication to two therapies (one example: clonazepam) is required. Initial/renewal durations are noted (initial and renewal as specified in entry).

    • Prescriber: neurologist or in consultation with neurologist
    • LGS prerequisite: trial of or contraindication to two therapies (example: clonazepam)
    • Initial/renewal durations per product entry
    Prior Authorization

    Carglumic acid prior auth specifics

    Carglumic acid prior authorization requires diagnostic confirmation for acute or chronic hyperammonemia etiologies (e.g., NAGS gene mutation by biochemical or genetic testing); durations vary by indication (acute: 7 days; chronic NAGS initial 6 months, renewal 12 months).

    • Diagnostic confirmation: genetic or biochemical testing per listed etiology
    • Duration: acute HA due to NAGS/PA/MMA = 7 DAYS; chronic NAGS initial = 6 MOS, renewal = 12 MOS
    Prior Authorization

    CIMZIA-STARTER prior authorization requirements

    CIMZIA‑STARTER requires prior authorization with indication‑specific initial requirements and step therapy in many indications (trials of or contraindication to preferred agents); step requirements are waived for pregnancy/breastfeeding/trying to conceive. Initial durations may be 6 months with renewals typically 12 months.

    • Document trials of specified preferred agents per indication or contraindication
    • Step waiver: pregnancy, breastfeeding, or trying to become pregnant
    • Initial duration commonly 6 months for some indications; renewal: 12 months
    Prior Authorization

    PA required; typical 12-month duration

    Prior authorization is commonly required for listed specialty products with a typical 12‑month approval period; confirm product‑specific PA criteria and prescriber requirements in the formulary entry.

    • Default coverage duration often 12 MONTHS
    • Verify prescriber restrictions per product
    Prior Authorization

    TAFINLAR soluble tablet — PA for inability to swallow capsules

    TAFINLAR soluble tablet (dabrafenib) soluble formulation may be prior authorized when the patient is unable to swallow capsules; PA criteria apply and coverage is typically listed as 12 months.

    • Authorization condition: inability to swallow TAFINLAR capsules
    • Coverage duration: 12 MONTHS
    Prior Authorization

    INQOVI — PA required

    INQOVI (decitabine/cedazuridine) is subject to prior authorization with a coverage duration of 12 months and indications per All FDA‑approved Indications.

    • Coverage duration: 12 MONTHS
    • Indications: All FDA‑approved Indications
    Prior Authorization

    Deferasirox — PA required

    Deferasirox products require prior authorization. Initial authorization is 6 months with renewal 12 months and documented laboratory thresholds (transfusion‑dependent: serum ferritin consistently >1000 mcg/L; NTDT: ferritin >300 mcg/L with LIC thresholds); trial of or contraindication to generic deferasirox formulations is required.

    • Transfusion‑dependent initial: ferritin >1000 mcg/L
    • NTDT initial: ferritin >300 mcg/L (two labs) AND LIC ≥5 mg Fe/g dry weight
    • Initial duration: 6 MONTHS; renewal: 12 MONTHS
    • Prerequisite: trial of or contraindication to generic deferasirox tablet or suspension
    Prior Authorization

    OSENVELT — PA required

    OSENVELT is subject to prior authorization with a coverage duration commonly listed as 12 months and indication scope per FDA labeling.

    • Coverage duration: 12 MONTHS
    • Indications: All FDA‑approved Indications
    Prior Authorization

    Topical and oral agents — PA required

    Topical and oral agents (e.g., diclofenac formulations, dimethyl fumarate) require prior authorization; typical authorization duration is 12 months and indications are listed as All FDA‑approved or All Medically‑accepted Indications where specified.

    • Typical coverage duration: 12 MONTHS
    • Confirm indication scope per product entry (FDA‑approved or medically accepted)
    Prior Authorization

    PA required; typical duration 12 months

    Prior authorization is commonly required across many formulary entries with a typical 12‑month coverage period (e.g., VUMERITY); verify product‑specific criteria when submitting a PA.

    • Confirm PA criteria and documentation per product entry
    • Typical duration: 12 MONTHS
    Prior Authorization

    Dronabinol PA and duration

    Dronabinol (oral capsule) requires prior authorization for nausea and vomiting associated with cancer with an initial coverage period of 6 months.

    • Coverage duration: 6 MONTHS for the listed indication (nausea/vomiting associated with cancer)
    • PA required
    Prior Authorization

    Prior authorization required for ORSERDU

    Prior authorization required for ORSERDU oral tablets; coverage duration listed as 12 months for FDA‑approved indications.

    • Coverage duration: 12 MONTHS
    • Indications: All FDA‑approved Indications
    Prior Authorization

    PA and duration for REVCOVI

    REVCOVI (elapegademase‑lvlr) requires prior authorization with initial approval for 6 months and renewal typically 12 months; initial requests must include confirmatory genetic testing or suggestive laboratory findings with hallmark signs/symptoms for ADA‑SCID and specialist prescribing.

    • Initial duration: 6 MONTHS; renewal: 12 MONTHS with evidence of improvement or maintenance of immune function
    • Diagnostic requirement: confirmatory genetic test OR suggestive labs (e.g., elevated deoxyadenosine nucleotide, lymphopenia) plus clinical signs/symptoms
    • Prescriber: immunologist, hematologist/oncologist, or metabolic disorder specialist
    Prior Authorization

    PA and prescriber restriction for TRIKAFTA

    TRIKAFTA (elexacaftor‑tezacaftor‑ivacaftor) requires prior authorization. Initial approval is for 6 months and renewal may be lifetime; initial requests must be prescribed by or in consultation with a pulmonologist or CF expert and the drug must not be used concurrently with another CFTR modulator.

    • Initial duration: 6 MONTHS; renewal: LIFETIME per entry
    • Prescriber: pulmonologist or cystic fibrosis expert
    • No concurrent use with another CFTR modulator
    Prior Authorization

    PA and renewal rules for ELREXFIO

    ELREXFIO (elranatamab‑bcmm) requires prior authorization with an initial 6‑month approval and 12‑month renewals; for relapsed/refractory multiple myeloma, renewal requires at least 24 weeks of treatment and documented response for at least 2 months.

    • Initial: 6 MONTHS; Renewal: 12 MONTHS
    • Renewal requirement for relapsed/refractory MM: ≥24 weeks treatment and response ≥2 months
    Prior Authorization

    PA and durations for PROMACTA

    Eltrombopag (PROMACTA/ALVAIZ) requires prior authorization for ITP and other indications. Initial ITP approvals are for 6 months with renewals of 12 months; initial requests must document platelet counts (<30 x10^9/L or <50 x10^9/L with prior bleeding), trial of or contraindication to corticosteroid or IVIG or insufficient response to splenectomy, and no concurrent use with other TPO‑RAs. For oral suspension packets, a trial of the formulary tablet or documentation of inability to tolerate tablets is required.

    • Initial ITP platelet criteria: <30 x10^9/L OR <50 x10^9/L with prior bleeding
    • Initial duration: 6 MONTHS; Renewal: 12 MONTHS
    • Document trial/contraindication to corticosteroid or IVIG or insufficient response to splenectomy
    • No concurrent use with other TPO‑RAs
    • For suspension packets: trial of tablet formulation or intolerance to tablets required
    Prior Authorization

    Eltrombopag prior authorization

    Prior authorization is required for eltrombopag products; initial ITP approvals are 6 months and renewals 12 months, contingent on meeting platelet thresholds and other specified criteria.

    • Ensure required baseline platelet counts and prior therapy documentation are submitted
    • No concurrent TPO‑RA use
    Step Therapy

    Abatacept (ORENCIA) step therapy

    Step therapy for abatacept (ORENCIA) in RA: trial of or contraindication to 3 months of one conventional synthetic DMARD (e.g., methotrexate at ≥20 mg/week or maximally tolerated dose) is required before approval.

    • Document trial duration (3 months) and dosing if methotrexate was used (≥20 mg/week or maximally tolerated)
    Step Therapy

    Prerequisite therapy trials

    Prerequisite therapy trials are required for many indications (e.g., RA, psoriasis, ankylosing spondylitis). Providers must document trials of conventional synthetic DMARDs, topical/systemic therapies, phototherapy, NSAIDs, or other specified agents, or document contraindications/intolerance.

    • Provide documentation of prior therapy trials and durations per indication (e.g., 3 months for DMARDs, 3 months for oral immunosuppressants for moderate‑severe psoriasis)
    Step Therapy

    Step or prerequisite therapy details

    Step therapy details vary by product and indication; examples include trials of oral immunosuppressants or phototherapy for psoriasis and an NSAID trial for ankylosing spondylitis prior to biologic approval.

    • Confirm required prior agents (e.g., cyclosporine, methotrexate, tacrolimus, PUVA for psoriasis) and document failure, intolerance, or contraindication
    Step Therapy

    Kineret step therapy

    Kineret (anakinra) step therapy: for RA an initial trial of or contraindication to two preferred agents is required prior to initiation.

    • Document trials of two preferred agents or contraindications
    Step Therapy

    Step therapy / prerequisite trials for Otezla

    Otezla initiation requires trials of or contraindications to specified conventional systemic or topical therapies or phototherapy for the indicated psoriasis severity; document these prior therapies when submitting a PA.

    • For mild PSO: trial of one conventional systemic OR one topical therapy
    • For moderate‑severe PSO: ≥3‑month trial of one oral immunosuppressant or PUVA, or contraindication/intolerance
    Step Therapy

    Step therapy requirement for specific indications

    Certain indications require failure of multiple prior systemic therapies (example: chronic graft‑vs‑host disease requires failure of at least two systemic therapy lines, one being JAKAFI); document prior systemic therapy history accordingly.

    • Provide history of prior systemic therapy lines and reason for failure/intolerance
    Step Therapy

    Prerequisite therapy noted

    Prerequisite therapy requirements are noted in several product entries (field 'Prerequisite Therapy: Yes'); ensure documentation of trials or contraindications per the product’s PA entry.

    • Check the product entry for the number and identity of prerequisite agents required
    Step Therapy

    Bosutinib step therapy note

    Bosutinib lists prerequisite therapy as required; submit documentation of prior therapy as indicated by the product entry when requesting prior authorization.

    • Ensure prior therapy documentation is submitted (product entry notes Prerequisite Therapy: Yes)
    Indication scopeAll FDA‑approved indications for abaloparatide
    Prerequisite therapyNone required
    Coverage duration for listed oncology products
    Typical coverage duration12 MONTHS (coverage duration listed for multiple oncology agents, e.g., VERZENIO, abiraterone products)
    Indication scopeAll FDA‑approved indications (per product entries)
    Part B applicabilityCommonly: No
    Psoriasis body surface area
    Psoriasis BSA threshold for systemic biologic initiation>= 3% body surface area OR lesions affecting hands/feet/face/scalp/genital area
    Mild disease definition<3% BSA or SPGA score of 2 or PASI score 2–9
    Documentation requiredBSA, SPGA or PASI score must be provided with PA request
    NYHA class for ATTR-CM
    NYHA class requirementNYHA class I, II, or III heart failure required for initial ATTR‑CM authorization
    Diagnostic confirmationStrongly positive Tc‑99m‑PYP bone scan OR tissue biopsy with chemical typing confirming transthyretin
    Prescriber requirementPrescribed by or in consultation with a cardiologist, ATTR specialist, or medical geneticist
    Methotrexate dosing trial
    Methotrexate dosing for DMARD trial>= 20 mg per week OR maximally tolerated dose when methotrexate was tried
    Duration of DMARD trialTrial of or contraindication to 3 months of one conventional synthetic DMARD for RA initial requests
    Alternate DMARD documentationIf methotrexate not used, document trial of another conventional synthetic DMARD or contraindication
    PrescriberPrescribed by or in consultation with cardiologist, ATTR specialist, or medical geneticist
    Conventional synthetic DMARD trial for RA
    Required trial durationTrial of or contraindication to 3 months of one conventional synthetic DMARD is required prior to biologic for RA
    Methotrexate standardIf methotrexate tried, trial at >=20 mg/week or maximally tolerated dose is expected
    Prescriber documentationPrescribed by or in consultation with a rheumatologist for RA/PJIA
    Plaque psoriasis severity
    Plaque psoriasis severity threshold>= 3% body surface area OR lesions affecting hands, feet, face, scalp, or genital area
    Mild disease criteria<3% BSA OR SPGA score of 2 OR PASI score 2–9
    Prior therapy requirementFor moderate‑to‑severe: at least a 3‑month trial of one oral immunosuppressant (e.g., cyclosporine, methotrexate, tacrolimus) or PUVA unless contraindicated
    RA DMARD trial requirement
    RA DMARD trial requirementTrial of or contraindication to 3 months of one conventional synthetic DMARD; if methotrexate tried, dose >=20 mg/week or maximally tolerated dose
    DocumentationProvide dosing history and reason for intolerance/contraindication if applicable
    No concurrent biologicNo concurrent use with another systemic biologic or targeted small molecule for same indication
    CAPS / DIRA diagnostic criteria
    Diagnostic evidence for CAPS/DIRAGenetic testing for gain‑of‑function mutations OR objective inflammatory markers (elevated CRP/ESR/SAA) plus characteristic clinical features
    Clinical features examplesUrticarial‑like rash, cold‑triggered episodes, sensorineural hearing loss, musculoskeletal symptoms, chronic aseptic meningitis (CAPS); pustular psoriasis‑like rash, osteomyelitis (DIRA)
    PrescriberSpecialist involvement (e.g., rheumatologist) expected for initial requests
    Mild vs Moderate-to-Severe Psoriasis
    Mild psoriasisPsoriasis covering <3% BSA OR SPGA score of 2 OR PASI score 2–9
    Moderate-to-severe psoriasisPsoriasis covering >=3% BSA or lesions affecting hands/feet/face/scalp/genitalia (qualifies for systemic biologic therapy)
    Assessment measuresBSA, SPGA, or PASI scores required for PA submission
    Ph+ CML with T315I or previously treated
    Ph+ CML populations coveredPreviously treated Ph+ CML and Ph+ CML with T315I mutation
    Required testingMutational analysis (BCR‑ABL1 mutation profile) prior to initiation
    Guideline alignmentTherapy appropriateness per NCCN treatment recommendations
    Initial / Renewal durations example (BENLYSTA)
    Example initial/renewal durationsBENLYSTA: Initial authorization 6 months; renewal 12 months with documentation of clinical improvement for SLE
    Prescriber requirementPrescribed by or in consultation with a rheumatologist for SLE; lupus nephritis requires rheumatologist or nephrologist
    Concurrent therapyRenewal requires ongoing background therapy (corticosteroids, antimalarials, NSAIDs, or immunosuppressives) and documented benefit
    Coverage duration of service authorized (commonly 12 MONTHS)
    Common default coverage duration12 MONTHS (commonly listed for many products)
    ExceptionsSome products have 6‑month initial approvals with 12‑month renewals (e.g., BENLYSTA, deferasirox initial 6 months)
    Part B notePart B applicability commonly listed as 'No' for many specialty drugs in this extract
    PAH diagnostic criteria (right heart catheterization thresholds)
    RHC diagnostic thresholds for PAHmean PAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units (required for bosentan PA)
    Prescriber requirementPrescribed by or in consultation with a cardiologist or pulmonologist
    Safety exclusionsDo not initiate if ALT/AST >3x ULN or bilirubin increase ≥2x ULN; no concurrent use with cyclosporine A or glyburide
    Hereditary angioedema (HAE) confirmation
    HAE confirmation testingType I or II HAE: complement testing (C1‑INH protein, C4, C1‑INH functional levels, C1q) required; Type III documented clinically
    PrescriberPrescribed by or in consultation with hematologist, immunologist, allergist, or pulmonologist
    Concurrent prophylaxisNot on concurrent alternative prophylactic HAE agent for initial/renewal
    NAGS-related hyperammonemia
    NAGS-related HA confirmationBiochemical or genetic confirmation of NAGS gene mutation required for acute or chronic hyperammonemia due to NAGS
    Duration for acute vs chronicAcute HA due to NAGS/PA/MMA: 7 days; Chronic HA due to NAGS: initial 6 months, renewal 12 months
    Renewal evidenceChronic NAGS renewal requires documented clinical improvement
    NR-axSpA diagnostic support
    NR‑axSpA diagnostic supportElevated CRP above ULN OR sacroiliitis on MRI supports diagnosis for NR‑axSpA initial approval
    PrescriberSpecialist involvement (rheumatologist) expected for initial requests
    Related criteriaInitial duration typically 6 months; renewal 12 months with documented benefit
    Ph+ CML definition
    DefinitionPhiladelphia chromosome‑positive chronic myeloid leukemia (Ph+ CML)
    Required testingMutational analysis (BCR‑ABL1 mutation profile) required prior to initiation for previously treated patients
    Coverage duration12 MONTHS (as listed)
    dalfampridine ER indication definition
    IndicationImprovement in walking ability for patients with multiple sclerosis
    Prescriber requirementPrescribed by or in consultation with a neurologist; documentation of walking disability (e.g., bilateral lower extremity impairment)
    Coverage duration12 MONTHS (initial/renewal listed)
    NTDT definition
    NTDT definition (laboratory)Serum ferritin consistently above 300 mcg/L (at least two values in prior 3 months) with LIC thresholds specified
    Initial LIC thresholdLIC >= 5 mg Fe/g dry weight for NTDT initial authorization
    PrescriberPrescribed by or in consultation with a hematologist or hematologist/oncologist
    NOH orthostatic BP drop
    Orthostatic BP drop criterion>=20 mmHg systolic OR >=10 mmHg diastolic within 3 minutes of standing (documented)
    Measurement requirementsBaseline seated and standing blood pressure readings required
    PrescriberPrescribed by or in consultation with neurologist or cardiologist
    ADA‑SCID definition
    ADA‑SCID confirmationConfirmatory genetic test OR suggestive labs (e.g., elevated deoxyadenosine nucleotide levels, lymphopenia) plus hallmark signs/symptoms (recurrent infections, failure to thrive, persistent diarrhea)
    PrescriberPrescribed by or in consultation with immunologist, hematologist/oncologist, or metabolic disorder specialist
    Initial/renewal durationsInitial: 6 months; Renewal: 12 months contingent on improved/maintained immune function
    ITP definition
    ITP diagnostic definitionPersistent or chronic immune thrombocytopenia (ITP) with platelet thresholds and prior therapy requirements specified for eltrombopag
    Initial platelet thresholdsPlatelet count <30 x10^9/L OR <50 x10^9/L with a prior bleeding event
    Prerequisite therapyTrial of or contraindication to splenectomy and trial/contraindication to one corticosteroid or IVIG as specified
    ITP (persistent or chronic)
    Persistent/chronic ITP criteriaITP requiring platelet count thresholds and prior therapy documentation for eltrombopag coverage
    Initial versus renewal durationsInitial approval: 6 months; Renewal: 12 months (requires improvement in platelet counts or reduced bleeding)
    Formulation trialFor oral suspension packets, trial of formulary tablet version is required or documentation patient cannot tolerate tablets